Literature DB >> 19794040

Emergence of hepatitis C virus genotype 4: phylogenetic analysis reveals three distinct epidemiological profiles.

Joep de Bruijne1, Janke Schinkel, Maria Prins, Sylvie M Koekkoek, Sem J Aronson, Marijn W van Ballegooijen, Hendrik W Reesink, Richard Molenkamp, Thijs J W van de Laar.   

Abstract

Hepatitis C virus (HCV) genotype 4 (HCV-4) infection is considered to be difficult to treat and has become increasingly prevalent in European countries, including The Netherlands. Using a molecular epidemiological approach, the present study investigates the genetic diversity and evolutionary origin of HCV-4 in Amsterdam, The Netherlands. Phylogenetic analysis of the NS5B sequences (668 bp) obtained from 133 patients newly diagnosed with HCV-4 infection over the period from 1999 to 2008 revealed eight distinct HCV-4 subtypes; the majority of HCV-4 isolates were of subtypes 4d (57%) and 4a (37%). Three distinct monophyletic clusters were identified, with each one having a specific epidemiological profile: (i) Egyptian immigrants infected with HCV-4a (n = 46), (ii) Dutch patients with a history of injecting drug use infected with HCV-4d (n = 44), and (iii) Dutch human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) infected with HCV-4d (n = 26). Subsequent molecular clock analyses confirmed that the emergence of HCV-4 within these three risk groups coincided with (i) the parenteral antischistosomal therapy campaigns in Egypt (1920 to 1960), (ii) the popularity of injecting drug use in The Netherlands (1960 to 1990), and (iii) the rise in high-risk sexual behavior among MSM after the introduction of highly active antiretroviral therapy (1996 onwards). Our data show that in addition to the influx of HCV-4 strains from countries where HCV-4 is endemic, the local spread of HCV-4d affecting injecting drug users and, in recent years, especially HIV-positive MSM will further increase the relative proportion of HCV-4-infected patients in The Netherlands. HCV-4-specific agents are drastically needed to improve treatment response rates and decrease the future burden of HCV-4-related disease.

Entities:  

Mesh:

Year:  2009        PMID: 19794040      PMCID: PMC2786681          DOI: 10.1128/JCM.01146-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  36 in total

1.  Diversity and origin of hepatitis C virus infection among unpaid blood donors in the Netherlands.

Authors:  Thijs J W van de Laar; Marco H G M Koppelman; Akke K van der Bij; Hans L Zaaijer; H Theo M Cuijpers; Cees L van der Poel; Roel A Coutinho; Sylvia M Bruisten
Journal:  Transfusion       Date:  2006-10       Impact factor: 3.157

2.  Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users.

Authors:  Charlotte H S B van den Berg; Colette Smit; Margreet Bakker; Ronald B Geskus; Ben Berkhout; Suzanne Jurriaans; Roel A Coutinho; Katja C Wolthers; Maria Prins
Journal:  Eur J Epidemiol       Date:  2007-03-03       Impact factor: 8.082

3.  Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours.

Authors:  Mark Danta; David Brown; Sanjay Bhagani; Oliver G Pybus; Caroline A Sabin; Mark Nelson; Martin Fisher; Anne M Johnson; Geoffrey M Dusheiko
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

4.  Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men.

Authors:  Thijis van de Laar; Oliver Pybus; Sylvia Bruisten; David Brown; Mark Nelson; Sanjay Bhagani; Martin Vogel; Alex Baumgarten; Marie-Laure Chaix; Martin Fisher; Hannelore Gotz; Gail V Matthews; Stefan Neifer; Peter White; William Rawlinson; Stanislav Pol; Jurgen Rockstroh; Roel Coutinho; Greg J Dore; Geoffrey M Dusheiko; M Danta
Journal:  Gastroenterology       Date:  2009-05       Impact factor: 22.682

Review 5.  Hepatitis C genotype 4: What we know and what we don't yet know.

Authors:  Sanaa M Kamal; Imad A Nasser
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

6.  Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic.

Authors:  Anouk T Urbanus; Thijs J van de Laar; Ineke G Stolte; Janke Schinkel; Titia Heijman; Roel A Coutinho; Maria Prins
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

7.  Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak?

Authors:  I Giraudon; M Ruf; H Maguire; A Charlett; F Ncube; J Turner; R Gilson; M Fisher; S Bhagani; M Johnson; S Barton
Journal:  Sex Transm Infect       Date:  2007-10-11       Impact factor: 3.519

8.  Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences.

Authors:  Donald G Murphy; Bernard Willems; Marc Deschênes; Nir Hilzenrat; Roger Mousseau; Sidney Sabbah
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

9.  Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.

Authors:  Charlotte Van Den Berg; Colette Smit; Giel Van Brussel; Roel Coutinho; Maria Prins
Journal:  Addiction       Date:  2007-09       Impact factor: 6.526

10.  Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam.

Authors:  Thijs J W van de Laar; Richard Molenkamp; Charlotte van den Berg; Janke Schinkel; Marcel G H M Beld; Maria Prins; Roel A Coutinho; Sylvia M Bruisten
Journal:  J Hepatol       Date:  2009-06-18       Impact factor: 25.083

View more
  36 in total

1.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

2.  Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA.

Authors:  S Pas; R Molenkamp; J Schinkel; S Rebers; C Copra; S Seven-Deniz; D Thamke; R J de Knegt; B L Haagmans; M Schutten
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

Review 3.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  [Not Available].

Authors:  Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

5.  The full-length genome sequences of nine HCV genotype 4 variants representing a new subtype 4s and eight unclassified lineages.

Authors:  Ling Lu; Yan Xu; Jie Yuan; Chunhua Li; Donald G Murphy
Journal:  Virology       Date:  2015-04-05       Impact factor: 3.616

Review 6.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster.

Authors:  J Verbeeck; L Kwanten; F D'Heygere; A Beguin; S Michiels; I Desombere; G Leroux-Roels; P Lemey; F Nevens; M Van Ranst
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-10       Impact factor: 3.267

8.  CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults.

Authors:  Mark Hull; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Giguère; Pierre Côté; Marc Poliquin; Curtis Cooper
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

9.  Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia.

Authors:  Chaturaka Rodrigo; Auda A Eltahla; Rowena A Bull; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Chris Estes; Homie Razavi; Andrew R Lloyd; Fabio Luciani
Journal:  J Infect Dis       Date:  2016-08-28       Impact factor: 5.226

10.  Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam.

Authors:  Peter V Markov; Thijs J van de Laar; Xiomara V Thomas; Sem J Aronson; Christine J Weegink; Guido E van den Berk; Maria Prins; Oliver G Pybus; Janke Schinkel
Journal:  J Virol       Date:  2012-05-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.